Case Study

Successfully Filing An IND Using Single Cell Cloning System


Biotheus Inc. was granted an IND in March 2020 for its bispecific therapeutic asset, PM8001. Regulatory approval was attained with help from the Solentim VIPS™ system for single cell cloning and clonality reporting. Because of the ease of use and reliability of the VIPS, valuable time was freed up as well as resources to help with platform development and to support the discovery team for other R&D activities. 

A system like VIPS is important for a small biotech start-up like Biotheus that needs to streamline and accelerate their pipeline development and push multiple lead candidates through to CHO pool generation and cell line selection. 


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online